Guided Therapeutics’ LuViva® Honored as Finalist in the Medical Device Excellence Awards

  Guided Therapeutics’ LuViva® Honored as Finalist in the Medical Device
  Excellence Awards

Business Wire

NORCROSS, Ga. -- April 9, 2014

Guided Therapeutics, Inc. (OTCBB: GTHP) (OTCQB: GTHP), today announced that
the LuViva® Advanced Cervical Scan, its non-invasive device used to detect
cervical disease instantly at the point of care, has been selected as a
finalist in the Hospital Devices and Therapeutic Products’ category of the
17^th Annual Medical Device Excellence Awards (MDEA) competition. Selected
products excel in the areas of product innovation, design and engineering
achievement, end-user benefit, and cost-effectiveness in manufacturing and
healthcare delivery. Winners will be announced at the 2014 MDEA Ceremony held
Wednesday, June 11, 2014 in conjunction with the MD&M East event at the Jacob
K. Javits Convention Center in New York.

“We are extremely pleased to be chosen as a finalist for this prominent
award,” said Gene Cartwright Chief Executive Officer of Guided Therapeutics.
“Being recognized by the Medical Design and Diagnostic Industry (MD+DI)
reinforces the exceptionality and innovation that is at the fundamental core
of the technology behind LuViva as well as the benefits it provides to not
only the patient but the healthcare system as well. We would also like to
recognize and thank our collaborative partner in the design process, Big Bang
of Decatur, Georgia, for their commitment to LuViva.”

The MDEA is committed to searching worldwide for the highest caliber finished
medical devices, products, systems, or packaging available on the market. The
awards program celebrates the achievements of the medical device
manufacturers, their suppliers, and the many people behind the
scenes—engineers, scientists, designers, and clinicians—who are responsible
for the cutting-edge products that are saving lives; improving patient
healthcare; and transforming medtech—one innovation at a time. Entries are
judged by an impartial panel of medtech experts comprised of a balance of
practicing doctors, nurses, and technicians alongside industrial designers,
engineers, manufacturers, and human factors experts. MDEA jurors
comprehensively review entries based on the following criteria: the ability of
the product development team to overcome all challenges so the product meets
its clinical objectives; innovative use of materials, components, and
processes; user-related functions improving healthcare delivery and changing
traditional medical attitudes or practices; features providing enhanced
benefits to the patient and end-user in relation to clinical efficacy;
manufacturing cost-effectiveness and profitability; and healthcare system
benefits such as improved accessibility, efficacy, or safety, in addition to
providing attention to a critical unmet clinical need.

The Medical Design Excellence Awards competition is presented by UBM Canon and
by Medical Device and Diagnostic Industry (MD+DI). Visit www.MDEAwards.com for
more info or e-mail mdea@ubm.com.

About Guided Therapeutics

Guided Therapeutics, Inc. (OTCBB: GTHP) (OTCQB: GTHP) is the maker of a rapid
and painless testing platform based on its patented biophotonic technology
that utilizes light for the early detection of disease at the cellular level.
The Company’s first product is the LuViva® ^ Advanced Cervical Scan, a
non-invasive device used to detect cervical disease instantly and at the point
of care. In a multi-center clinical trial, with women at risk for cervical
disease, the technology was able to detect cervical cancer up to two years
earlier than conventional modalities, according to published reports. Guided
Therapeutics is also developing a non-invasive test for the early detection of
esophageal cancer using the technology platform. For more information, visit:
www.guidedinc.com.

The Guided Therapeutics LuViva^® Advanced Cervical Scan is an investigational
device and is limited by federal law to investigational use. LuViva, the wave
logo and "Early detection, better outcomes" are registered trademarks owned by
Guided Therapeutics, Inc.

Forward-Looking Statements Disclaimer: A number of the matters and subject
areas discussed in this news release that are not historical or current facts
deal with potential future circumstances and developments. The discussion of
such matters and subject areas is qualified by the inherent risks and
uncertainties surrounding future expectations generally and also may
materially differ from Guided Therapeutics’ actual future experience involving
any of or more of such matters and subject areas. Such risks and uncertainties
include those related to the early stage of products in development, the
uncertainty of market acceptance of products, the uncertainty of development
or effectiveness of distribution channels, the intense competition in the
medical device industry, the uncertainty of capital to develop products, the
uncertainty of regulatory approval of products, dependence on licensed
intellectual property, as well as those that are more fully described from
time to time under the heading “Risk Factors” in Guided Therapeutics’ reports
filed with the SEC, including Guided Therapeutics’ Annual Report on Form 10-K
for the fiscal year ended December 31, 2012, and subsequent quarterly reports.

Photos/Multimedia Gallery Available:
http://www.businesswire.com/multimedia/home/20140409005771/en/

Multimedia
Available:http://www.businesswire.com/cgi-bin/mmg.cgi?eid=50841158&lang=en

Contact:

Guided Therapeutics
Bill Wells, 770-242-8723
or
Investors:
Cameron Associates
Alison Ziegler, 212-554-5469
 
Press spacebar to pause and continue. Press esc to stop.